Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients
Status:
Not yet recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
This is a single-center, single-arm, phase 2 study to evaluate the efficacy and safety of
camrelizumab in combination with cetuximab and chemotherapy as first-line for patients with
relapsed/metastastic head and neck squamous cell carcinoma